Vaidyanathan, Akshayaa
van der Lubbe, Marly F. J. A.
Leijenaar, Ralph T. H.
van Hoof, Marc
Zerka, Fadila
Miraglio, Benjamin
Primakov, Sergey
Postma, Alida A.
Bruintjes, Tjasse D.
Bilderbeek, Monique A. L.
Sebastiaan, Hammer
Dammeijer, Patrick F. M.
van Rompaey, Vincent
Woodruff, Henry C.
Vos, Wim
Walsh, Seán
van de Berg, Raymond
Lambin, Philippe
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions
Article History
Received: 20 May 2020
Accepted: 19 January 2021
First Online: 3 February 2021
Competing interests
: M.F.J.A van der Lubbe, Marc van Hoof, Sergey Primakov, A.A. Postma, T.D. Bruintjes, M.A.L. Bilderbeek , Hammer Sebastiaan, P.F.M. Dammeijer, V. van Rompaey and R. van de Berg have no competing interests Fadila Zerka, Akshayaa Vaidyanathan, and Benjamin Miraglio are salaried employees of Oncoradiomics SA. Dr Philippe Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic/DNAmito, Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics, BHV, Merck, Varian, Elekta, ptTheragnostic and Convert pharmaceuticals. Dr Lambin has shares in the company Oncoradiomics SA, Convert pharmaceuticals SA and The Medical Cloud Company SPRL and is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures and three non-issues, non licensed patents on Deep Learning-Radiomics and LSRT (N2024482, N2024889, N2024889. Ralph T.H. Leijenaar has shares in the company Oncoradiomics and is co-inventor of an issued patent with royalties on radiomics (PCT/NL2014/050728) licensed to Oncoradiomics. Sean Walsh and Wim Vos have shares in the company Oncoradiomics. Henry C. Woodruff has minority shares in the company Oncoradiomics.